Comparative behavioural effects of typical and atypical antipsychotic drugs in rhesus monkey

European Journal of Pharmacology

Volumn 462, Issue 1-3, 2003, Pages 133-138

  Kumar, Rakesh ^a,b   Palit, Gautam ^a   Dhawan, Bhola N ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b Government Post Graduate College   (India)

Author keywords

(Rhesus monkey); Behaviour; Chlorpromazine; Clozapine; Haloperidol; Risperidone

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT; RISPERIDONE;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ARTICLE; BEHAVIORAL SCIENCE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; EXTRAPYRAMIDAL SYMPTOM; FEMALE; LOCOMOTION; MALE; NONHUMAN; OBSERVATION; PRIORITY JOURNAL; PSYCHOANALYSIS; RHESUS MONKEY; SEDATION; SOCIAL BEHAVIOR; VIDEORECORDING;

EID: 0037458687     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(02)02957-6     Document Type: Article

References (36)

1. Baldessarini R.J. Drugs and the treatment of psychiatric disorders. Hardman J.G., Limbird L.E., Goodman Gilaman A. Goodman and Gilman The Pharmacological Basis of Therapeutics. 10th ed. 2001;447-484 McGraw-Hill, New York, NY.
2. Bernstein I.S., Judge P.G., Ruchlmann T.E. Kinship association and social relationships in rhesus monkeys (Macaca mulatta). Am. J. Primatol. 31:1993;41-53.
3. Bleich A., Brown S.I., Kahn R., Vanpraag H.M. The role of serotonin in schizophrenia. Schizophr. Bull. 14:1988;297-315.
4. Breir A., Malhotra T.P., Elman A.K., Edler C.M., Weisenfeld N.I., Picker D. Effect of typical and atypical antipsychotic drug treatment on amphetamine induced dopamine release in patients with psychotic disorder. Neuropsychopharmacology. 20:1999;340-345.
5. Casey D.E. Serotonergic and dopaminergic aspect of neuroleptic induced extra pyramidal syndromes in non-human primates. Psychopharmacology. 112:1993;555-559.
6. Casey D.E. Behavioural effect of sertindole, respiridone, clozapine and haloperidol in cebus monkeys. Psychopharmacology. 124:1996;134-140.
7. Casey D.E. Tardive dyskinesia: pathophysiology and animal models. J. Clin. Psychiatry. 4:2000;5-9.
8. Casey D.E., Hansen T.E. Schizophrenia psychopharmacology; resperidone and clozapine. Jefferson J.W., Griest J.H. The Psychiatric Clinics North America: Annual of Drug Therapy. 1995;119-149 Saunders, Philadelphia.
9. Chesler E.J., Salamone J.D. Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Pharmacol. Biochem. Behav. 54:1996;619-624.
10. Chouinard G., Jones B., Remington G., Bloom D., Addington D., MacEwan G.W., Labelle A., Beauclair L., Arnott W. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. J. Clin. Psychopharmacol. 13:1993;25-40.
11. Cluttenbrock T.H. Primate social organization and ecology. Nature. 250:1974;539-542.
12. Crow T.J. Schizophrenia. Crow T.J. Disorders of Neurohumoral Transmission. 1986;287-340 Academic Press, New York, NY.
13. Duncan G.E., Zorn S., Leiberman J.A. Mechanism of typical and atypical antipsychotic drug action in relation to dopamine and NMDA receptor hypothesis of schizophrenia. Mol. Psychiatry. 4:1999;418-428.
14. Hicks P.B. The effect serotonergic agents on haloperidol induced catalepsy. Life Sci. 47:1990;1609-1615.
15. Hippius H. A historical perspective of clozapine. J. Clin. Psychiatry. 60:1999;22-23.
16. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiatry Clin. Neurosci. 4:1999;90-98.
17. Kane J.M. Clinical efficacy of clozapine in treatment of refractory schizophrenia: an overview. Br. J. Psychiatry. 160:1992;41-45.
18. Kane J.M., Honigfeld G., Singer J. Clozapine for the treatment of resistant schizophrenia; a double-blind comparison with chlorpromazine. Arch. Gen. Psychiatry. 45:1988;789-796.
19. Krupp P., Barnes P. Clozapine associated agranulocytosis: risk and etiology. Br. J. Psychiatry. 160:1992;38-39.
20. Liebman J., Neale R. Neuroleptic-induced acute dyskinesias in squirrel monkeys correlation with propensity to cause extrapyramidal side effects. Psychopharmacology. 8:1980;25-29.
21. Marder S.R., Meibach R.C. Risperidone in the treatment of schizophrenia. Am. J. Psychiatry. 151:1994;825-835.
22. Meltzer H.Y., Stahl S.M. Meltzer H.Y. Novel Antipsychotic Drugs. Schizophr. Bull. 1992;19-76 Raven Press, New York, NY.
23. Moller J.E., Muller H., Borison R.L. A path analytical approaches to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients: a revaluation of the North American risperidone study. Eur. Arch. Psychiatry Clin. Neurosci. 245:1995;45-49.
24. Palit G. Quantitative assessment of amphetamine induced behavioural changes in rhesus monkey Macaca mulatta. Indian J. Exp. Biol. 33:1995;980-982.
25. Palit G., Kumar R., Gupta M.B., Saxena R.C., Patnaik G.K., Dhawan B.N. Quantification of behaviour in social colonies of rhesus monkey. Indian J. Physiol. Pharmacol. 41:1997;219-226.
26. Palit G., Kumar R., Chowdhary S.R., Gupta M.B., Saxena R.C., Srimal R.C., Dhawan B.N. A primate model of anxiety. Eur. Neuropsychopharmacol. 8:1998;195-201.
27. 2+ Channel blockers in Rhesus monkey. Eur. J. Pharmacol. 412:2001;139-144.
28. Peukens J. Risperidone in the treatment of patients with chronic schizophrenia: a multinational multicentre double blind parallel group study versus haloperidol. Br. Psychiatry. 166:1995;712-726.
29. Sanger D.J., Perrault G. Effect of typical and atypical antipsychotic on response decrement patterns in rats. J. Pharmacol. Exp. Ther. 272:1995;708-713.
30. Sassernath E.N., Chapman L.F. Primate social behaviour as a method of analysis of drug action, studies with THC in monkey. Fed. Proc. 35:1976;2238-2244.
31. Schlemmer R.F., Davis J.M. A comparison of three psychomimetic induced models of psychosis in non-human primate social colonies. Miczek K.A. Ethanopharmacology: Primate models of Neuropsychiatric Disorders. 1983;33-78 Alanliss, New York, NY.
32. Stip E. Novel antipsychotics; issues and controversies, typicality of atypical antipsychotics. J. Psychiatry Neurosci. 25:2000;137-153.
33. Stitzer M.L., Griffiths R.R., Bigelow G.E., Liebman I. Human social conversation: effect of ethanol, secobarbitol and chlorpromazine. Pharmacol. Biochem. Behav. 14:1981;353-360.
34. Vellucci S.A. Primate social behaviour - anxiety or depression. Pharmacol. Ther. 47:1990;167-180.
35. Vrtunski P.B., Konicki P.E., Jaskin G.E., Brescan D.W., Kwon K.Y., Jurjus G. Clozapine effects on force control in schizophrenic patients. Schizophr. Res. 34:1998;39-48.
36. Worrel J.A., Marken P.A., Beekman S.E., Ruether V.L. Atypical antipsychotic agents: a critical review. Am. J. Health-Syst. Pharm. 57:2000;238-255.